Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03650556 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 224
- Enrollment target
NCT03650556 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 224 participants.
The verdict
NCT03650556, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 224 participants
- Enrollment target
Study Summary
This clinical investigation is intended to demonstrate the safety and effectiveness of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for use in cardiac electrophysiological mapping and for the treatment of drug-refractory, recurrent symptomatic persistent atrial fibrillation (AF) when used in conjunction with a compatible radiofrequency (RF) generator and three-dimensional mapping system. This clinical investigation will be conducted under an investigational device exemption (IDE) and is intended to support market approval of the TactiCath SE ablation catheter for the treatment of drug refractory, symptomatic persistent atrial fibrillation in the United States.
Interventions
- DEVICE TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2021-01-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03650556
The ClinicalTrials.gov registry entry for NCT03650556 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ is the first listed.
NCT03650556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03650556 about?
NCT03650556 is a clinical study titled "Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation". This clinical investigation is intended to demonstrate the safety and effectiveness of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for use in cardiac electrophysiological mapping and for the treatment of drug-refractory, recurrent symptomatic persistent atrial fibr...
What is the current status of trial NCT03650556?
This trial is currently completed. It is a NA study. The enrollment target is 224 participants. The study started on 2018-09-28. Estimated completion is 2021-01-11.
What interventions are being tested in trial NCT03650556?
The interventions under investigation include: TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (DEVICE).
Who is sponsoring clinical trial NCT03650556?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.